Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (41)
  • Allergen immunotherapy (81)
  • AllergoOncology (15)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (235)
  • Allied health and primary care (20)
  • Anaphylaxis (113)
  • Artificial Intelligence (12)
  • Asthma (185)
  • Basic immunology (58)
  • x Biologicals (90)
  • Biomarkers (64)
  • Comparative veterinary allergology (1)
  • COVID19 (11)
  • Dermatology (125)
  • Drug allergy (172)
  • ENT (29)
  • Environmental allergy and climate change (31)
  • x Eosinophilic esophagitis (21)
  • Epidemiology (66)
  • Epithelial cell biology (8)
  • Food allergy (195)
  • Genomics and proteomics (17)
  • Immune deficiencies and autoimmunity (80)
  • Immunomodulation and nutrition (13)
  • Infections (27)
  • Insect venom hypersensitivities (19)
  • Mastocytosis and mast cells (24)
  • Microbiome (9)
  • Occupational allergy (27)
  • Ocular allergy (5)
  • One Health (13)
  • Pediatrics (144)
  • Prevention (40)
  • Systems medicine (13)
Poster available until
  • Until platform closure (2)
Poster categories
  • e-Thematic Poster Session (6)
  • Thematic Poster Session (88)
keywords
Session Reference
  • L-TPS02 (9)
  • L-TPS07 (11)
  • L-TPS08 (1)
  • L-TPS09 (3)
  • L-TPS10 (1)
  • L-TPS11 (2)
  • L-TPS19 (1)
  • L-TPS21 (1)
  • TPS06 (8)
  • TPS09 (3)
  • TPS10 (2)
  • TPS17 (4)
  • TPS18 (9)
  • TPS29 (1)
  • TPS31 (1)
  • TPS34 (1)
  • TPS51 (1)
  • TPS52 (5)
  • TPS55 (10)
  • TPS56 (5)
  • TPS57 (1)
  • TPS63 (1)
  • TPS67 (9)
  • TPS68 (1)
  • TPS69 (2)
  • TPS70 (9)
  • TPS73 (1)
109 results
Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

000854 - Allergen and Panallergen Sensitization Profile in Pediatric Eosinophilic Esophagitis Patients: a single centre experience

Thumbnail

D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis

Thumbnail

D2.118 - Eosinophilic Esophagitis and Atopy: A Shared Mechanism of Type 2 Inflammation

Thumbnail

D2.195 - Clinical characteristics of eosinophilic esophagitis and gastroenteritis in Korean children: a single-center study

Thumbnail

D3.384 - PREVALENCE OF SENSITIZATION TO PANALLERGENS AND IgG4 PROFILES AGAINST SPECIFIC FOODS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OF ALLERGIC PHENOTYPE

Thumbnail

D3.399 - Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis

Thumbnail

D3.402 - Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis

Thumbnail

D3.403 - Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study

Thumbnail

D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent

Thumbnail

D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution

Pagination

  • First page First
  • Previous page Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM